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Acute myeloid leukemia (AML) is an aggressive hematological malignancy, and the mechanism underlying immune system 
involvement in leukemia development is unclear. In the present study, we utilized a myeloid/lymphoid or mixed-lineage leu-
kemia; translocated to, 3 (MLLT3/MLL-AF9)-induced AML mouse model with or without exposure to irradiation. We found 
that the leukemia cells could survive and expand in hosts with intact immune systems, whereas leukemia progression was ac-
celerated in mice with impaired immune systems. Moreover, the leukemia cells escaped from host immunosurveillance via ed-
iting their immunogenicity, including the up-regulation of an inhibitory antigen (i.e., CD47) and the down-regulation of active 
antigens (i.e., CD86, CD54, retinoic acid early transcript (RAE), histocompatibility 2, D region locus b (H2-Db) and H2-Dd). 
Natural killer (NK) cells were activated in the early phase of AML progression, whereas T cells were stimulated in the late 
phase. Furthermore, NK cell depletion showed that NK cells were necessary for the elimination of leukemia cells in our AML 
mouse model. Notably, CD155/CD226 primarily mediated the interaction between NK cells and leukemia cells and contribut-
ed to the antitumor effects of NK cells during the early phase of AML. Clinical data from patients with diverse hematological 
malignancies showed that CD155 expression was decreased in hematological malignancies. Taken together, our results 
demonstrate that NK cells play a pivotal role in immunosurveillance against leukemia cells during the early stage of AML 
primarily through the CD226/CD155 interaction; however, NK cells are not sufficient to eliminate leukemia cells. 
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Acute myeloid leukemia (AML) is a heterogeneous disorder 
characterized by the clonal expansion of distinct leukemia 
stem cells (LSCs) [1–3]. Although the majority of patients 
achieve complete remission with standard induction chem-
otherapy, the relapse rate remains high [4]. Allogeneic stem 
cell transplantation is curative for some AML patients,  
possibly due to the therapeutic graft-versus leukemia   
effect [5]. Although only a minority of patients are suitable 
for transplantation, the success of this procedure has en-
couraged the investigation of other immune strategies 
against leukemia [6–8]. 
Leukemia-associated antigens (LAA) are expressed on 
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leukemia progenitors [9]. Some LAAs, such as proteinase 3 
(PR3) and Wilm’s tumor antigen 1 (WT1), elicit a cytotoxic 
T-cell response [10]. Moreover, AML cells employ immune 
evasion strategies to escape immunosurveillance (i.e., the 
up-regulation of calreticulin/cluster of differentiation 47 
(CD47) [11], programmed death-ligand 1 (PD-L1)/CD274) [12] 
and toll-like receptors [13]). Notably, clinical data based on 
strategies targeting these antigens are diverse, suggesting 
that leukemia cells may evolve gradually and exhibit inter-
play with the immune system during leukemia progression. 
The immune system not only eliminates developing leu-
kemia but also sculpts the immunogenicity of leukemia 
cells. Modified leukemia cells could survive in immuno-
competent hosts. The adaptive immune response dominated 
by T cells has been demonstrated to be an essential compo-
nent of cancer immunosurveillance [14,15]. Natural killer 
(NK) cells play a key role in the immune antitumor re-
sponse, as demonstrated by the low relapse rate obtained for 
allogenic stem cell transplantation when there is a mismatch 
in NK inhibitory receptors between the host and the  
graft [16]. Interestingly, recent studies reported that AML 
blasts induced long-lasting changes in NK cells (i.e., im-
pairing their effect or function and reducing the competence 
of the innate immune system), thereby favoring leukemia 
survival [17,18]. Moreover, NK cells in AML patients 
showed diminished expression of several activating recep-
tors that contributed to impaired NK cell function, and as a 
consequence AML blasts escaped from NK cell immuno-
surveillance [19]. However, the mechanism by which leu-
kemia cells survive in immunocompetent hosts and what 
role NK cells precisely play during leukemia development 
in a more clinically relevant setting are unclear. 
In this study, we used a previously reported AML mouse 
model (MLL-AF9-induced AML) [20,21]. Established 
MLL-AF9 leukemia cells were transplanted into immuno-
competent mice with or without irradiation. We found that 
the destruction of the immune system by irradiation accel-
erated the progression of leukemia. Established leukemia 
cells have evolved by modifying antigens to escape immu-
nosurveillance, especially compared with hematopoietic 
stem progenitor cells (HSPCs). Nevertheless, modified leu-
kemia cells could still activate innate and adaptive immune 
responses during different phases of the disease. Leukemia 
development was largely inhibited by NK cells even in the 
absence of adaptive immunity. NK cells were mainly acti-
vated by the upregulation of activating ligands (i.e., CD155 
and RAE on leukemia cells) during the early phase of the 
disease. Notably, the activated ligands were down regulated 
in LSCs, which occupy the bone marrow (BM) pool during 
the late phase. Clinical data from patients with diverse he-
matological malignancies also showed reduced CD155 ex-
pression. These results indicate that NK cells play a vital 
role in the antitumor response primarily during the early 
phase of MLL-AF9 AML. Furthermore, leukemia cells 
modify their immunogenicity to generate a repertoire that is 
capable of survival in immunocompetent hosts.  
1  Materials and methods  
1.1  In vivo mouse model  
C57BL/6-CD45.2 and Nod-scid mice between 6–8 weeks of 
age were maintained in the animal facility of the State Key 
Institute of Hematology (SKLEH). All experiments were 
conducted under the protocol approved by the Institutional 
Animal Care and Use Committees of SKLEH. Lin stem 
and progenitor cells were enriched from the bone marrow 
cells of C57BL/6-CD45.2 mice using lineage cell depletion 
beads. Enriched Lin cells were infected with a retrovirus 
carrying MSCV-MLL-AF9-IRES-GFP (green fluorescent 
protein) as previously described. After 2 d of transduction, 
approximately 1×106 cells were injected into the lethally 
irradiated (9.5 Gy) C57BL/6-CD45.2 recipients. The dosage 
was split into 4.75 Gy twice a day. Mice were sacrificed at 
the terminal stage of leukemia (~60 d), and primary leuke-
mic cells (P0) in the bone marrow were harvested for the  
in vivo experiments. 
1.2  Sample preparation 
Lin cells were isolated using a negative magnetic bead se-
lection protocol (Miltenyi, Bergisch Gladbach, Germany). 
CD4+ T cells, CD8+ T cells and NK cells were sorted by 
FACS (Becton Dickinson, Franklin Lakes, USA). T cells 
were cultured in Roswell Park Memorial Institute (RPMI) 
1640 medium supplemented with 10% fetal bovine serum 
(FBS) and IL-2 (20 ng mL1). 
1.3  Flow cytometry 
A total of 5×106–1×107 harvested cells were suspended in 
100 μL of FACS buffer and stained with the corresponding 
antibodies at 4°C for the appropriate amount of time. An-
ti-CD3, anti-CD4, anti-CD8, anti-CD45R, anti-CD11b, an-
ti-Gr-1, and anti-Ter-119 constituted the Lineage mixture 
(Lin mix). The following antibodies were used to study 
HSCs and HPCs: Lin mix, anti-c-Kit, anti-Sca1, anti-CD34, 
anti-CD150, anti-CD16/32 (FcR), anti-CD135 (Flt3/Flk2), 
anti-CD45.1 and anti-CD45.2 (BD Biosciences). Anti-Mac1 
and anti-Gr1 were used to distinguish the myeloid lineage. 
Anti-CD3, anti-CD4 and anti-CD8 were used to study T 
cells, whereas anti-NK1.1 was used to analyze NK cells. 
Leukemic cells could be distinguished by reading the fluo-
rescence of the GFP marker. 4′,6-diamidino-2-phenylindole  
(DAPI) was applied to distinguish dead cells. Cell analyses 
were performed on the LSRII flow cytometer (Becton 
Dickinson, Franklin Lakes, USA). Cell sorting assays were 
performed on the AriaIII flow cytometer (Becton Dickin-
son, Franklin Lakes, USA). 
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1.4  NK cell depletion 
The C57BL/6 and Nod-scid mice were irradiated with 4.5 
and 2 Gy, respectively, and intraperitoneally injected with 
an anti-CD122 (100 μg) antibody 1 d post-irradiation. Two 
days later, NK cell depletion in the BM and spleen was con-
firmed by flow cytometry. 
1.5  CFSE staining 
Single-cell suspensions of T cells were resuspended at a 
density of 5–10×106 per mL in PBS (pre-warmed to room 
temperature). CFDA SE; 5, 6-carboxyfluorescein diacetate, 
succinimidyl ester (CFSE) was added to the desired final 
concentration (1 μmol L1), mixed immediately and incu-
bated for 10 min at room temperature in the dark. The la-
beling was stopped by the addition of 4–5 volumes of cold 
complete medium, and the cells were incubated on ice for  
5 min. The cells were washed 3 times with complete medium, 
and the T cells were cultured in RPMI 1640 with 10% FBS. 
1.6  Quantitative RT–PCR (qRT-PCR) 
Total RNA was isolated using the Qiagen RNeasy mini kit. 
qRT-PCR assays were performed on the StepOne real-time 
PCR system (Applied Biosystems). 
1.7  Statistical analysis 
The GraphPad Prism 5.0 and SPSS 17.0 statistical software 
were used for statistical analysis. An unpaired Student’s t 
test and analysis of variance (ANOVA) were applied to 
generate P values for most datasets. 
2  Results 
2.1  Destruction of the immune system accelerates leu-
kemia progression 
To study the interplay between leukemia cells and the im-
mune system, we used our previously reported leukemia 
mouse model [20,21]. Lin BM HSPCs were purified from 
mice and transfected with the MSCV-MLL-AF9-IRES-GFP 
retrovirus as previously described. Transformed cells were 
transplanted into lethally irradiated mice. The recipients 
developed leukemia within 2 months (Figure 1A). The es-
tablished leukemia cells were positive for GFP and myeloid 
lineage markers, which indicated an AML phenotype. The 
primary leukemic cells were able to induce AML when in-
jected into secondary recipients, demonstrating the trans-
plantability of the leukemic cells in our system. Then, the 
established leukemic cells could be used to perform the 
subsequent experiments. 
Irradiation has been reported to damage the immune sys-
tem [22]. To determine whether the breakdown occurred in 
our experiment system, two irradiation doses (4.5 and 6 Gy) 
were chosen. NK cells and T cells were selected as the rep-
resentatives for innate immunity and adaptive immunity, 
respectively. There was no significant difference in T cells 
in the BM between the irradiated group and the 
non-irradiated group. In contrast, T cells were obviously 
decreased in the spleen, peripheral blood (PB) and thymus 
of the irradiated group (Figure 1B and C). Notably, NK 
cells were significantly reduced in the BM, spleen and PB 
of the irradiated mice (Figure 1B and C). These phenomena 
suggest that the irradiation causes damage to the mouse 
immune system as expected.  
Next, we examined whether the immune system partici-
pated in leukemia progression. A total of 5×104 leukemic 
cells were transplanted into irradiated or non-irradiated 
mice. The irradiated mice treated with a dose of either 4.5 
or 6 Gy showed a shorter lifespan compared with the 
non-irradiated mice (Figure 1D). These results demonstrat-
ed that the destruction of the immune system by irradiation 
could accelerate the progression of AML. Surprisingly, in 
contrast to a previous report using a myeloid/lymphoid or 
mixed-lineage leukemia; translocated to, 1 (MLLT1/ 
MLL-ENL) leukemia model [23], the non-irradiated recipi-
ents in our model succumbed to AML despite their intact 
immune systems. This suggests that the immunosurveil-
lance effect of the immune system during the development 
of MLL-AF9 AML is limited. 
2.2  Modified immunogenicity of leukemic cells is in-
volved in leukemia initiation 
The leukemic cells could survive in immunocompetent mice 
and cause a leukemia outbreak. Therefore, we hypothesized 
that the immunogenicity of leukemic cells could be altered 
by MLL-AF9, especially compared with normal HSPCs, 
because some antigen molecules have been reported to be 
dominantly expressed on malignant cells. First, we evaluat-
ed the expression of the inhibitory antigens CD47 and 
CD274. We found higher expression of CD47 in the leuke-
mic cells, but no distinction was found when CD274 ex-
pression was compared with HSPCs. Then, we analyzed the 
expression of the activating ligands CD86 [24] and MHCII 
and found a 50% down-regulation of CD86. CD54 [25] was 
also reduced in leukemic cells, which was similar to  
findings reported for patients with lymphoproliferative dis-
orders [26]. We also detected some ligands of activated re-
ceptors on NK cells, which could enhance NK-mediated 
cytotoxicity. Among these ligands, CD155 exhibited in-
creased expression on leukemic cells compared with 
HSPCs, whereas RAE and H2-Dd had reduced expression. 
These changes in leukemic cell antigens may imply the 
modification of the immunogenicity of leukemic cells is in 
concurrence with leukemia progression (Figure 2A and B). 
2.3  T cells and NK cells are activated during different 
stages of leukemia progression 
To investigate the interplay between leukemic cells and the 
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Figure 1  Immune cells play a large role in anti-acute myeloid leukemia. A, Strategy used to establish MLL-AF9 leukemic mice. BM Lin cells were 
transduced with MSCV-MLL-AF9-IRES GFP for 48 h and then transplanted in lethally irradiated mice (9.5 Gy). Established MLL-AF9 leukemic cells were 
transplanted in recipient mice in subsequent experiments. B, Representative flow graphs showing the rates of T cells and NK cells in the BM and spleen of 
recipient mice 3 days post-irradiation. C, Percentages of T cells (upper panel) and NK cells (lower panel) in the recipient mice 3 days post-irradiation. Data 
represent the mean±SD (n=3 per group, 3 independent experiments). *: P<0.05; ***: P<0.001, one-way ANOVA analyses. D, Kaplan-Meier curves of the 
overall survival of irradiated or non-irradiated wild-type mice transplanted with MLL-AF9 leukemia cells (n=6). 
host immune system, we used immunocompetent mice 
transplanted with 1×106 established leukemic cells for the 
following experiments. The manageable and suitable leu-
kemia duration was performed as previously described. Af- 
ter transplantation with leukemic cells, the mice showed 
some fluctuation of immune cells. The percentage of T cells 
was obviously increased during the late stage (~day 20), 
whereas the percentage of NK cells gradually decreased. 
However, the total numbers of both cell types were reduced, 
especially during the late phase of leukemia (Figure 2C and 
D). 
Next, we investigated whether the changes in the im-
mune cells in leukemic mice had an antitumor effect in our 
model. Because T cells play a significant antitumor role, we 
sorted the GFPCD3+CD4+ T cells and GFPCD3+CD8+ T 
cells for mRNA analysis. The qRT-PCR results showed that 
transcription factors such as T-bet, RoRt, Foxp3 and Gata3 
were gradually upregulated in CD3+CD4+ T cells concomi-
tant with leukemia progression, especially during the late 
phase (day 14) of leukemia (Figure 3A). Cytotoxic mole-
cules, including IFN-, granzyme and perforin, showed 
higher expression levels in CD3+CD8+ T cells during the 
late stage (Figure 3B). To determine the activation of T 
cells in leukemic mice, we purified CD3+CD4+ and 
CD3+CD8+ T cells on day 14 and analyzed their prolifera-
tion by CFSE staining (Figure 3C). In line with the in vivo 
gene expression analyses, the percentage of dividing cells 
(% Divided) and average number of cell divisions 
(Div.Index) of T cells in mice with leukemia were signifi-
cantly upregulated after 48 h of culture in vitro (Figure 3D). 
In contrast, the cytotoxic molecules of NK cells (i.e., IFN-, 
granzyme and perforin) were activated during the early 
stage (day 7) but were markedly reduced to the basal level 
during the late stage (Figure 3E). These results suggest that   
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Figure 2  Change of the immune system during leukemia progression. A, 
Representative flow graphs showing the variation in immune antigen ex-
pression between LSK (HSPCs) and established leukemic cells. B, Histo-
grams showing the MFI of different immune antigens (n=3 per group, 3 
independent experiments). C and D, Histograms showing the statistical 
analysis of the percentages and absolute numbers of T cells (C) and NK 
cells (D) of mice at the indicated time points after the induction of leuke-
mia. Data represent the mean±SD (n=6 per group, 3 independent experi-
ments). **: P<0.01; ***: P< 0.001, one-way ANOVA analyses. 
T cells and NK cells are activated during the late stage and 
the early stage of the leukemia course, respectively, but 
these cells are not sufficient to eliminate the leukemic cells. 
Thus, we can infer that even the undamaged immune system 
cannot achieve the clearance of the evolving leukemic cells.  
2.4  NK cells play a vital but limited role in the fight 
against leukemia progression 
To determine the mechanism by which the activated im-
mune cells were involved in the progression of leukemia, 
MLL-AF9 leukemic cells were intravenously transferred 
into wild-type and Nod-scid (lacking T cells, B cells and 
NKT cells) mice. There were no significant differences in 
the survival curves of the Nod-scid and wild-type mice 
(Figure 4A). Next, to investigate the precise role of NK 
cells in AML, we used an anti-CD122 antibody to eliminate 
NK cells in both the wild-type and Nod-scid mice [27,28]. 
NK cells in the BM and spleen were significantly reduced 
after treatment with the anti-CD122 antibody (Figure 4B 
and C). Strikingly, NK cell-depleted WT mice showed ac-
celerated leukemia development (median 4 d less than the 
control) (Figure 4D), whereas the NK cell-depleted 
Nod-scid recipients showed a significantly increased accel-
eration of leukemia (median 8 d less than the control) (Fig-
ure 4E). These results suggest that NK cells play a signifi-
cant but not sufficient role in the elimination of leukemic 
cells. Thus, T cells are involved in the immunosurveillance 
of leukemia primarily through cooperation with NK cells. 
2.5  CD155/CD226 mainly mediates the interaction 
between NK cells and leukemic cells in AML 
To investigate the interaction between leukemic cells and 
NK cells, representative NK cell receptors and their specific 
ligands were analyzed during leukemia progression [29]. 
Consistent with the results of a previous study, we found the 
inhibition of natural killer group 2 membrane D (NKG2D) 
receptor [30,31] in NK cells but the upregulation of its lig-
and RAE in the late phase. These results confirmed that the 
NKG2D/RAE interaction was involved in the immunosur-
veillance activity of NK cells in AML (Figure 5A and C). 
Importantly, we found a gradual downregulation of 
DNAM-1 (CD226) in NK cells from leukemic mice at day 
10 (Figure 5A) and an early upregulation (day 7) and late 
(day 10 and 20) downregulation of its ligand CD155 (Figure 
5C). Together with the changes of gene expression in NK 
cells (Figure 2E), these results indicate that the 
CD226/CD155 interaction plays a vital role in the NK 
cell-mediated suppression of leukemia. Additionally, we 
also found the upregulation of MHC class I-H2Db, which 
may mediate resistance of the leukemic cells to NK cell 
killing (Figure 5C). In contrast, no significant difference or 
fluctuation was detected in the two other crucial active and 
inhibitory receptors of NK cells (i.e., NKP46 and NKG2A) 
(Figure 5B).  
Next, we investigated the effect of NK cells the immu-
nogenicity of leukemic cells. The changes in leukemic cell 
antigens were reanalyzed in NK cell-depleted mice. The 
median fluorescence intensity (MFI) of MHC class 
I-H2Dd/H2Db of leukemic cells showed inconsistent fluc-
tuation in the BM and spleen, whereas both CD155 and 
RAE of leukemic cells were upregulated in either the BM or 
spleen after NK cell depletion (Figure 5D and E). These 
results suggest that some leukemic cells down-regulate their 
active ligands for NK cells to escape the attack by NK cells. 
NK cells may kill leukemic cells that express higher levels 
of active signals. 
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Figure 3  Activated immune system in leukemic mice. A and B, qRT-PCR analysis showing the expression levels of candidate genes in GFPCD3+CD4+ 
(A) and GFPCD3+CD8+ (B) T cells at the indicated time points after leukemia cell transplantation. Data represent the mean±SD (n=6, 3 independent ex-
periments). *: P<0.05; **: P<0.01; ***: P< 0.001, Student’s t-test. C, Representative flow cytometry showing the proliferation of T cells based on CFSE 
staining of control and 14 d leukemic mice after culture for 48 h. D, The histograms show the percentages of dividing cells (% Divided) and the average 
number of cell divisions (Div. Index) of GFPCD3+CD4+ and GFPCD3+CD8+ cells. Data represent the mean±SD (n=3, 2 independent experiments). **: 
P<0.01; ***: P<0.001, Student’s t-test. E, qRT-PCR analysis showing the expression levels of candidate genes in GFPCD3NK1.1+NK cells.  
2.6  Active molecules of NK cells are selectively inhib-
ited in both LSCs and human hematological malignan-
cies 
To confirm the effects of active molecules of NK cells on 
the evolution of leukemic cells, we analyzed the expression 
of the main factors reported in previous studies [29]. The 
results showed that most molecules were reduced in AML 
LSCs (with the exception of CEACAM1) based on the un-
supervised clustering analysis (Figure 6A). Reduced ex-
pression of RAE, CD72 and CD155 on LSCs was observed 
compared to HSCs. Next, we analyzed the immunogenicity 
of hematological malignant cells in human samples using 
Oncomine analysis. Notably, the expression of CD155 was 
decreased in leukemia as well as lymphoma and myeloma 
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Figure 4  NK cells inhibit MLL-AF9 leukemia development even in the absence of adaptive immunity. A, Kaplan-Meier curves for the overall survival of 
C57BL/6-CD45.2 mice or Nod-scid mice transplanted with 5×105 MLL-AF9 leukemic cells (n=10 per group). B and C, The histograms show the efficiency 
of NK cell depletion in the BM and spleen by the anti-CD122 antibody (n=3, 2 independent experiments). ***: P<0.001, Student’s t-test. D, Kaplan-Meier 
curves for the overall survival of sublethally irradiated (4.5 Gy) C57BL/6-CD45.2 wild type mice or NK-depleted (anti-CD122) mice transplanted with 
1×105 MLL-AF9 leukemic cells (n=10 per group). E, Kaplan-Meier curves for the overall survival of sublethally irradiated (2 Gy) Nod-scid wild type mice 
or NK-depleted (anti-CD122) mice transplanted with 1×105 MLL-AF9 leukemic cells (n=10 per group). 
based on COPA analysis. Moreover, RAE was upregulated, 
and distinct fluctuations of H2-Dd were shown in hemato-
logical malignancies (Figure 6B). These results indicate that 
the survival of leukemic cells may be partially attributed to 
the low expression levels of active ligands for NK cells (i.e., 
CD155) in mice and humans. 
3  Disscusion 
Investigation into the interplay between the immunoediting 
of leukemic cells and the immune system is necessary for 
the development of novel agents that target leukemic cells 
and cooperate with conventional treatments. In the present 
study, we employed a previously reported MLL-AF9 leu-
kemic cell model to evaluate the interactions between leu-
kemic cells and the immune system (Figure 1A). We found 
more aggressive leukemia progression in mice with defi-
cient immune systems (Figure 1B–D). Moreover, the leu-
kemic cells established by MLL-AF9 could survive and 
expand in robust hosts with an intact immune system, pos-
sibly due to their modified immunogenicity. We summa-
rized the upregulation of CD47 and CD155 and the down-
regulation of active antigens (i.e., CD86, CD54, RAE, 
H2Db and H2-Dd) in leukemic cells compared with HSPCs 
(Figure 2A). NK cells were activated in the early phase and 
T cells were stimulated in the late phase of the disease to 
fight against the immuno-edited leukemic cells (Figure 
3A–E). Nevertheless, NK cells played a more significant 
role in the anti-leukemia response in AML, although they 
still exhibited some cooperative crosstalk with the adaptive 
immune system (Figure 4A–E). Additionally, we found that 
the anti-leukemia effect in AML mediated by NK cells 
mainly depended on the CD226/CD155 interaction (Figure 
5A–E). Importantly, some active antigens (i.e., CD155 for 
NK cells) showed reduced expression in LSCs and evolved 
leukemic cells from humans. In conclusion, NK cells play a 
significant role in immunosurveillance during the early 
phase of AML. NK cells may also participate in cooperative 
crosstalk with T cells to operate an immune response 
against leukemic cells though a mechanism that has yet to 
be defined (Figure 6C). 
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Figure 5  Expression of NK cell-activating ligands on leukemic cells. A and B, The histograms show the MFI of NK cell receptors at different 
post-leukemia time points (n=3, 3 independent experiments). ***: P<0.001, Student’s t-test. C, The histograms show the MFI of NK cell ligands on leukemic 
cells at different post-leukemia time points (n=3, 3 independent experiments). ***: P<0.001, Student’s t-test. D and E, The histograms show the variation of 
NK cell ligands on leukemic cells in wild type and NK cell-depleted mice (n=3, 3 independent experiments). ***: P<0.001, Student’s t-test. 
In line with previous studies, established leukemic cells 
expressed higher inhibitory antigens and lower active lig-
ands to escape immune attack, especially compared with 
HSPCs (Figure 2A). Additionally, leukemic cells exhibited 
CD155 upregulation and could activate NK cells during the 
early phase. J Nakata previously reported that the MLL- 
ENL oncogene could transform non-immunogenic hemato-
poietic cells into immunogenic cells that could be wholly 
eliminated [23]. Perhaps due to the different oncogenes and 
methods used, in our study the transplantation of leukemic 
cells ultimately led to animal death. Notably, we dynami-
cally monitored the immunogenicity of leukemic cells dur-
ing the progression of leukemia and observed the downreg-
ulation of CD155 and upregulation of RAE. Because clini-
cally evident leukemic cells may have been immunologi-
cally selected, they cannot fully reflect the integrated pro-
cess of leukemia progression [32]. We demonstrated the 
immunogenic fluctuations of established leukemic cells 
during disease progression, which may offer some insight 
into the evolution of leukemic cells.  
NK cell ligands were regarded as the intrinsic sensors  
of tumor transformation and an induced immune  
response [33,34]. NK cells were demonstrated to kill tumor 
cells due to the enforced expression of NK cell-activating 
ligands. These findings suggest that NK cells have the po-
tential to recognize and eliminate developing tumor cells 
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Figure 6  Expression of NK cell-activating ligands on hierarchical leukemic cells. A, Representative heat map of the NK cell-activating ligands in hierar-
chical hematopoietic cells based on the analysis of reported microarray data (GSE20377). Unsupervised clustering was performed using array tools. B, 
Summary of selected NK cell-activating ligands in leukemia, lymphoma and myeloma by the Oncomine database. Cancer Outlier Profile Analysis (COPA) 
and a t-test were used to quantify the expression patterns of selected genes. The range and median fractions of patients with selected outlier gene profiles in 
all datasets are shown. C, Schematic model of the interplay between the immune system and leukemia progression. NK cells perform crucial roles against 
leukemia in the early phase, whereas T cells attack leukemia in the late phase. Simultaneously, leukemia cells evolve by modifying the expression of im-
mune antigens to escape immunosurveillance. 
during the early stage of tumor development. In our study, 
we clearly demonstrated that NK cells performed an-
ti-leukemia activities during the early stage but were inhib-
ited during the late stage by CD226 and NKG2D downreg-
ulation (Figure 5A). Although NKG2D expression was only 
slightly decreased on day 20, the expression of its ligand 
RAE was remarkably increased (Figure 5C). NKG2D/RAE 
might also be involved in leukemia immunosurveillance, 
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which was reported in a previous MLL-ENL leukemia 
model. However, in our model we found the up-regulation 
of CD155 and the down-regulation of RAE at the initiation 
of leukemia, indicating that the activation of NK cells in the 
MLL-AF9 leukemia model occurred mainly through the 
CD226/CD155 interaction. Nevertheless, the crosstalk be-
tween different stimulatory pathways should be kept in 
mind in future studies. We also observed the upregulation of 
cytotoxic mole cules in activated NK cells, indicating that 
NK cells could directly kill malignant cells (Figure 3E). 
IFN- was also highly expressed in NK cells, which could 
in turn induce an adaptive immune response. Although the 
T cells in our model were activated during the late stage, for 
the short latency of our model, the precise crosstalk between 
NK cells and T cells requires further investigation. CD122 
is expressed at a lower level on subsets of T cells, B cells, 
monocytes and macrophages [35]. However, anti-CD122 
antibodies have been used to selectively deplete NK cells in 
previous studies [27,28]. Because impairment of NK cell 
cytotoxicity is associated with almost all hematological ma-
lignancies, restoration of normal NK function remains an 
attractive goal for immunotherapy [16,36]. 
In conclusion, we found that leukemic cells could survive 
and expand in hosts with intact immune systems. The leu-
kemic cells escaped from host immunosurveillance via ed-
iting their immunogenicity. NK cells were activated in the 
early phase, which was a necessary step for the elimination 
of leukemic cells. CD155/CD226 primarily mediated the 
interaction between leukemic cells and NK cells to achieve 
the antitumor effects of NK cells during the early phase of 
AML. The clinical data also showed that CD155 expression 
was decreased in leukemia. However, the precise mecha-
nisms underlying the involvement of the CD226/CD155 
interaction in AML immunosurveillance require further 
investigation using antibodies specific to CD155 and some 
target compounds. Our results demonstrate that NK cells 
play a significant role in immunosurveillance against leu-
kemic cells during the early stage of AML primarily 
through the CD226/CD155 interaction; however, NK cells 
are not sufficient to eliminate the leukemic cells. 
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